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Edited by Hans-Dieter KlenkAbstract Glycogen synthase kinase-3b (GSK-3b) is a key
component of several signaling pathways. We found that a short
variant of ‘TNF-like weak inducer of apoptosis’ (shortTWEAK)
formed a complex with GSK-3b in a yeast two-hybrid system.
We demonstrate that shortTWEAK and GSK-3b colocalize in
the nucleus of human neuroblastoma cells. We also show that
TWEAK is internalized in diﬀerent cell lines and that it
translocates to the nucleus. This event causes the degradation
of IBa, the nuclear translocation of both GSK-3b and p65, and
the induction of NF-B-driven gene expression. We demonstrate
that the induction of IL-8 expression by TWEAK can be
counteracted by LiCl. Taken together, these data suggest that
GSK-3b plays an important role in the signal transduction
pathway between TWEAK and NF-B.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Glycogen synthase kinase-3b (GSK-3b) phosphorylates and
thereby regulates the function of many metabolic, signaling
and structural proteins. Recently, it was reported that mice
with inactivated GSK-3b die during embryonic development
due to massive hepatocyte apoptosis, caused by a defect in the
NF-jB pathway. This defect was independent of DNA-bind-
ing activity, suggesting the involvement of GSK-3b in the
regulation of p65 transactivation [1]. The role of GSK-3b in
the regulation of NF-jB activation was also demonstrated by
other groups [2,3]. These data are in contradiction with the
demonstration that overexpression of a constitutive active
mutant of GSK-3b strongly inhibited NF-jB activation [4].* Corresponding author. Fax: +32-14-60-5380.
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Abbreviations: C.E., cytoplasmatic extract; N.E., nuclear extract; E-
TWEAK, protein encoded by pECFP-C1/TWEAK; E-shortTWEAK,
protein encoded by pECFP-C1/shortTWEAK; TWEAK-E, protein
encoded by pECFP-N1/TWEAK; shortTWEAK-E, protein encoded
by pECFP-N1/shortTWEAK; FL, full length IL-8 promoter construct;
98BP, 98 base pair IL-8 promoter construct; 3jB, construct containing
3 times IL-6 NF-jB responsive element
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doi:10.1016/j.febslet.2004.04.041Recent studies have indicated that GSK-3b localization is
dynamically regulated, but the mechanisms by which it is
controlled remain unclear. Although GSK-3b is found pre-
dominantly in the cytoplasm of most cells, it has been found to
enter the nucleus during S-phase of the cell cycle and during
apoptosis [5–8]. Analysis of the amino acid sequence does not
reveal the presence of any recognizable nuclear import or ex-
port sequences, but it was suggested that GSK-3b localization
may be regulated indirectly through associations with binding
proteins [9].
‘TNF-like weak inducer of apoptosis’ (TWEAK) is a novel
member of the TNF superfamily [10]. The TNF family mem-
bers, currently including at least 18 ligands and 28 receptors,
have pivotal roles in host defense, inﬂammation, apoptosis,
autoimmunity and organogenesis [11]. The extracellular se-
quence of TWEAK shows the greatest similarity to that of
TNF [12]. It was suggested that TWEAK exists in two diﬀerent
forms: an 18 kDa processed form which can be secreted into
the supernatant (sTWEAK) and a 30–35 kDa form with an
intact transmembrane domain [10]. sTWEAK induced apop-
tosis and NF-jB activation in human cell lines [12]. It was also
shown to act as a growth factor and as a potent inducer of
angiogenesis [13].
Fn14 was cloned from a human vein endothelial cell (HU-
VEC) cDNA library as a receptor for TWEAK [14]. TWEAK
mediates angiogenesis and endothelial cell proliferation by
interacting with Fn14 [15]. Fn14 can associate with four dis-
tinct TRAF family members (1, 2, 3 and 5) and stimulate the
NF-jB signaling pathway [16]. However, it was recently indi-
cated that a second TWEAK receptor exists on RAW cells that
is responsible for mediating TWEAK-induced diﬀerentiation
of RAW cells into osteoclasts, since ﬂow cytometry did not
reveal the expression of Fn14 on RAW cells [17].
In this paper, we demonstrate the involvement of GSK-3b in
the TWEAK/short variant of TWEAK (shortTWEAK) sig-
naling pathway. We found that GSK-3b and shortTWEAK
interacted in a yeast two-hybrid (Y2H) system. We observed
the nuclear localization of shortTWEAK and the colocaliza-
tion of GSK-3b and shortTWEAK in the nuclei of intact cells.
Our results indicate that TWEAK can exert its pro-inﬂam-
matory eﬀects without binding to its receptor Fn14 by inter-
nalizing the cells and translocating directly to the nucleus. This
event causes the nuclear translocation of GSK-3b and p65 in
these cells. TWEAK also activates the IL-8 promoter by directblished by Elsevier B.V. All rights reserved.
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LiCl, a known GSK-3b inhibitor.2. Materials and methods
2.1. Cell culture
SHSY-5Y cells were grown in DMEM supplemented with 1 non-
essential amino acids, 10% fetal calf serum (FCS), 2 mM L-glutamine
and 50 lg/ml gentamycin. Jurkat T cells were grown in RPMI 1640
medium, supplemented with 10% heat-inactivated FCS, 2 mM L-glu-
tamine and penicillin (100 U/ml)-streptomycin (0.1 mg/ml). L929 cells
were grown in DMEM supplemented with 5% newborn calf serum, 5%
FCS, 2 mM L-glutamine and penicillin (100 U/ml)–streptomycin (0.1
mg/ml) (Life Technologies).
2.2. Western blotting
Following cell lysis, equal amounts of protein were separated by
SDS–PAGE (Novex) and transferred to Immun-Blot PVDF mem-
branes (Bio-Rad), which were then incubated with antibodies against
TWEAK (S-20), p65 (C-20) or IjBa (C-21) (all three: Santa Cruz) or
against GSK-3b (Transduction Laboratories).
2.3. Constructs
mRNA was isolated from SHSY-5Y cells using the Dynabeads
mRNA Direct kit (Dynal), as recommended by the manufacturer. The
entire coding sequence of hTWEAK (Accession No. AF055872) was
RT-PCR generated from SHSY-5Y cell mRNA using the following
primers: TWEAK sense (50-ATGGCCGCCCGTCGGAGCCAGA-
GGCGGAGG-30) and TWEAK antisense (50-TCAGTGAACCTG-
GAAGAGTCCGAAGTAGGTGAGG-30). The Titan One Tube
RT-PCR Kit (Roche) was used according to the manufacturer’s in-
structions. The pCR-XL-TOPO/TWEAK sequence was veriﬁed by
sequence analysis.
An ATGwas attached in frame to the shortTWEAK sequence picked
up in the Y2H screen by PCR, thereby generating pCR-XL-TOPO/
shortTWEAK (forward primer: ATGGACCAGGAGGAGCTGGT-
GGC and reverse primer: TCAGTGAACCTGGAAGAGTC).
The coding sequence of GSK-3b was isolated from the pCR-XL-
TOPO/GSK-3b plasmid by PCR and subcloned into pECFP-C1 and
pECFP-N1, thereby generating pECFP-C1/GSK-3b (encoding C-
GSK-3bÞ and pECFP-N1/GSK-3b (encoding GSK-3b-C).
The TWEAK and shortTWEAK sequences were subcloned into
pEYFP-C1 and pEYFP-N1. This resulted in the generation of pEYFP-
C1/TWEAK (encoding E-TWEAK), pEYFP-C1/shortTWEAK
(encoding E-shortTWEAK), pEYFP-N1/TWEAK (encoding
TWEAK-E) and pEYFP-N1/shortTWEAK (encoding shortTWEAK-E).
2.4. Transfections
SHSY-5Y cells were plated at 140 000 cells/well on poly-L-lysine
coated 8-well chamber slides (LAB-TEK). They were transfected with
0.5 lg DNA and 0.8 ll Lipofectamine 2000 (Invitrogen) per well ac-
cording to the manufacturer’s protocol. The living cells were visualized
16–24 h after transfection using a Zeiss Axiovert 100 M microscope
with a Plan Apochromat 63/0.14 oil objective.
2.5. Internalization experiments
Recombinant human TWEAK (sTWEAK), comprising the 155 C-
terminal AA of TWEAK, was purchased from PeprotechEC. The
protein was reconstituted in 10 mM Na phosphate buﬀer, pH 7.5, to a
concentration of 1 mg/ml and further diluted with water to a con-
centration of 0.1 mg/ml. sTWEAK was diluted in fresh medium and
added to the cells at 1 lg/million cells.
2.6. Nuclear and cytoplasmic extract preparations
Nuclear and cytoplasmic extracts were prepared using the NE-PER
kit (Pierce) according to the manufacturer’s protocol and the extracts
were used for western blotting.
2.7. NF-jB-dependent reporter assay
L929 cells were stably transfected with the luciferase (luc) expression
vector pGL3basic, in which the luc gene was regulated by either the
human full length IL-8 promoter (FL) or a shorter 98 base pair con-struct (98BP) (free gifts of Dr. M. Mukaida [18]) or else a synthetic
construct containing 3 times the IL-6 NF-jB responsive element (3jB),
as described by Dr. W. Vanden Berghe et al. [19]. All reporter cells are
also stably expressing b-galactosidase (b-gal) under the control of a
house-keeping promoter (mouse 3-phosphoglycerate kinase) which
was a kind gift of Dr. P. Soriano [20] (Fred Hutchinson Cancer Re-
search Centre, Seattle, WA). Cells were seeded to conﬂuency and
treated with TNF (2000 IU/ml), sTWEAK and/or 40 mM LiCl for 6 h.
Cells were lysed and both luc and b-gal contents were measured. By
correcting luc for b-gal values, we can compensate for diﬀerences in
protein concentration in the various samples.3. Results
3.1. Identiﬁcation of a new GSK-3b-binding partner
A human brain cDNA library was screened by the yeast two-
hybrid assay method (Y2H) using wild-type GSK-3b as a bait.
14 clones encoded a polypeptide of 193 amino acid residues
corresponding to the 193 C-terminal amino acids of TWEAK
(AA 57–250). We named this new variant shortTWEAK for
shorter form of TWEAK. Comparison of the 50 end of short-
TWEAKwith the sequence of human chr17:72251296–7260089
(http://genome-test.cse.uscs.edu) revealed that the 50 end of
shortTWEAK corresponds to the start of exon 2 (BI 766766)
and that shortTWEAK thus only consists of the extracellular
part of TWEAK. All of the 14 clones missed an ATG but we
decided to attach a start codon by means of PCR and thereby
generate shortTWEAK (193 AA), since TWEAK exists as a
naturally processed soluble cytokine (sTWEAK) (155 AA) [10]
and Y2H results show that it is this part of TWEAK that is
necessary for the interaction with GSK-3b.
3.2. Localization of TWEAK and shortTWEAK in human
SHSY-5Y cell line
TWEAK was predicted to be a type II transmembrane
protein without apparent signal sequence at the amino termi-
nus [12]. To examine the localization of TWEAK and short-
TWEAK, we cloned both cDNAs into the pEYFP-vector and
used both N- and C-terminal EYFP-fusion proteins to exclude
spatial interference of the EYFP-fusion protein.
Cells expressing E-TWEAK displayed a bright signal in either
plasma or nuclearmembrane (Fig. 1A), indicating that TWEAK
canbe located inboth cellularmembranes.These cells underwent
a morphology change soon after the expression of E-TWEAK,
but survived, suggestive of a diﬀerentiation-type event.
TWEAK-E expressing cells show localization throughout the
cytoplasm in vesicle-like structures (Fig. 1B), thereby excluding
the diﬀerentiation of E-TWEAKexpressing cells to be caused by
the fusion of TWEAK and EYFP. The cytoplasmic localization
of TWEAK-E is probably caused by cleavage at the stalk region
of TWEAK (which has been previously reported) [10], resulting
in a cleavage product which lacks the transmembrane part.
Cells expressing shortTWEAK-E showed a nuclear locali-
zation of shortTWEAK (Fig. 1C). Immunoﬂuorescent analysis
also indicated nuclear localization of TWEAK (results not
shown). PSORT II analysis indicates that both TWEAK and
shortTWEAK contain two possible nuclear localization sig-
nals (NLS) at AA 90–93 and AA 96–102 or AA 35–38 and AA
41–47, respectively. These NLS conﬁrmed our ﬁndings that
shortTWEAK can be a nuclear protein. In contrast, E-short-
TWEAK expressing cells showed localization throughout the
whole cytoplasm (see Fig. 1D) in vesicle-like structures possi-
bly caused by shielding of these NLS by the EYFP-protein.
Fig. 2. Internalization and nuclear translocation of sTWEAK in dif-
ferent cell lines. Jurkat, SHSY-5Y and L929 cells were treated with 1
lg sTWEAK/million cells for an increasing amount of time (10, 25, 40,
and 60 min: lanes 2–5) after which nuclear (N.E.) and cytoplasmic
(C.E.) extracts were prepared. C.E. and N.E. were immunoblotted for
TWEAK. Untreated cells served as negative control (lane 1).
Fig. 1. Subcellular localization of TWEAK, shortTWEAK and GSK-
3b. (A–F) Confocal images of SHSY-5Y cells transfected with vectors
encoding E-TWEAK (A), TWEAK-E (B), shortTWEAK-E (C), E-
shortTWEAK (D), C-GSK-3b (E) or GSK-3b-C (F). (G,H) Confocal
analysis of SHSY-5Y cells co-expressing C-GSK-3b or GSK-3b-C and
shortTWEAK-E: colocalization is shown as a merge of the two signals
in the nuclei of the cells.
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GSK-3b in human cells
Next, we studied the localization of GSK-3b and TWEAK
versus shortTWEAK in living cells. Again, both N- and C-
terminal GSK-3b-ECFP-fusion proteins were used. C-GSK-3b
and GSK-3b-C expressing cells show localization throughout
the cytoplasm and not at all in the nucleus (Fig. 1E and F).
There was no colocalization when co-expressing GSK-3b,
either fused to the N-terminus or C-terminus of ECFP, with
E-TWEAK, TWEAK-E or E-shortTWEAK.
In contrast, colocalization in the nucleus was observed when
we expressed GSK-3b, either fused to the N-terminus or C-
terminus of ECFP, together with shortTWEAK-E (Fig. 1G
and H). Cells expressing both proteins show apparent locali-
zation of GSK-3b, both nuclear and cytoplasmic. So, there is a
clear translocation of GSK-3b to the nucleus when expressed
simultaneously with shortTWEAK-E.
3.4. Internalization and subsequent translocation to the nucleus
of sTWEAK in diﬀerent cell lines
sTWEAK was added to diﬀerent cell lines and we noticed
that sTWEAK could be found in the nucleus of Jurkat, SHSY-
5Y and L929 cells as soon as 10 min after the addition of
sTWEAK to the cells. The signal reaches a maximum at about
25 min and stays the same until 60 min after the start of the
incubation (Fig. 2).
Futaki reviewed that arginine-rich peptides possess the po-
tential to translocate through the cell membrane and suggested
the presence of an ubiquitous internalization mechanism forarginine-rich peptides. The sequence of sTWEAK also shows
multiple arginines located near the N-terminus (AA 1–10:
MKGRKTRRAR). So, sTWEAK might use the same inter-
nalization mechanism as other membrane-permeable basic
peptides, such as HIV-1 Tat, Antennapedia, human cFos and
cJun peptides [21].
This result oﬀers a new mode of action for TWEAK inde-
pendent of its receptor Fn14 or any other receptor, since L929
and Jurkat cells were reported to lack Fn14 expression on the
surface [22,23].
3.5. Eﬀects of sTWEAK on the localization of GSK-3b and on
the NF-jB pathway
GSK-3b is a cytosolic protein, but it is translocated into the
nucleus when activated [24,25]. Since shortTWEAK colocalizes
with GSK-3b in the nucleus of living cells, we wanted to see if
the subcellular localization of GSK-3b changes after addition
of sTWEAK to living cells. It was shown that sTWEAK in-
creases NF-jB-speciﬁc DNA-binding activity [12] and since
previous studies have shown that p65, and not p50, exerts
transactivation potential, we examined whether there was also
a translocation of p65 to the nucleus. As shown in Fig. 3A and
B, as soon as 10 min after starting the incubation, we can ob-
serve an induction of both GSK-3b and p65 nuclear levels.
To examine if this eﬀect was mediated by the canonical NF-
jB activation pathway, we also analyzed the TWEAK-medi-
ated IjBa degradation levels. We could see a time-dependent
decrease in IjBa levels starting from 5 to 10 min, reaching a
maximal decrease at 40 min. IjBa levels increased again after
60 min (Fig. 3C).
The rapid translocation of both GSK-3b and p65 to the
nucleus, together with the eﬀects seen on the IjBa levels,
indicates that sTWEAK is a very potent stimulator for the
translocation of GSK-3b and a strong activator of the ca-
nonical NF-jB pathway.
3.6. Eﬀect of sTWEAK on NF-jB-speciﬁc DNA-binding
activity and on the induction of the IL-8 promoter
Several groups reported that TWEAK induced NF-jB-spe-
ciﬁc DNA-binding activity and stimulated IL-8 secretion
[10,12,26,27]. We examined if sTWEAK could induce NF-
jB-dependent activation of the IL-8 promoter. Therefore, we
used cell lines that express diﬀerent IL-8 promoter-driven lu-
ciferase constructs: i.e., a full length IL-8 promoter construct
(FL), or a 98 base pair fragment upstream of the start codon
(containing C/EBP and NF-jB binding sites) (98BP) or else a
construct containing 3NF-jB binding sites (3jB).
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Fig. 4. Eﬀect of sTWEAK, TNF and LiCl on diﬀerent IL-8 promoter
constructs. (A) Concentration dependent induction of NF-jB-depen-
dent IL-8 promoter constructs. Stable cell lines expressing FL, 98BP
and 3jB promoter constructs were incubated with diﬀerent concen-
trations of sTWEAK (0.25; 0.5; 1; 2; 5; 10 and 20 nM). (B) Stimulation
of diﬀerent IL-8 promoter constructs with sTWEAK and TNF. Stable
cell lines expressing FL, 98BP and 3jB promoter constructs were in-
cubated with 20 nM sTWEAK or 2000 IU/ml TNF. (C) Inﬂuence of 40
mM LiCl on sTWEAK-stimulation. Stable cell lines expressing FL,
98BP and 3jB promoter constructs were incubated with 40 mM LiCl,
20 nM sTWEAK, or a combination. The results are expressed as fold
induction compared to the non-treated condition. Data (meansS.D.)
are from at least three independent experiments.
Fig. 3. Translocation of GSK-3b and p65 to the nucleus and degra-
dation of IjBa in cells treated with sTWEAK. (A–B) Jurkat and L929
cells were treated with 1 lg sTWEAK/million cells for an increasing
period of time (10, 25, 40, and 60 min: lanes 2–5) after which N.E. and
C.E. extracts were prepared. C.E. and N.E. were immunoblotted for
GSK-3b (A) and p65 (B). Untreated cells served as negative control
(lane 1). (C) L929 cells were treated with 1 lg sTWEAK/million cells
for an increasing amount of time (5, 10, 25, 40, and 60 min: lanes 2–6)
after which total cell lysates were prepared. Cell lysates were immu-
noblotted for IjBa. Untreated cells served as negative control (lane 1).
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concentration-dependent manner after stimulation of the cells
with sTWEAK (Fig. 4A). The activity increased for all three
cell lines using diﬀerent concentrations in the range 0.25–20
nM. We used 20 nM sTWEAK in further experiments (see
Fig. 4A). These data prove that IL-8 synthesis induced by
TWEAK, as reported previously [10], is a direct consequence
of the activation of the IL-8 promoter by TWEAK.
The stimulation of IL-8 promoter activity by sTWEAK re-
sults in a 2.5 to 3-fold induction in comparison with untreated
cells and the relative inducibility remains comparable for the
various cell lines (Fig. 4B). The fact that sTWEAK not only
aﬀects the complete IL-8 promoter but also the minimal NF-
jB promoter indicates that the eﬀect is mainly caused by the
NF-jB activation. This is also supported by Harada et al. [28]
who suggested that the TWEAK-induced secretion of IL-8 by
HUVEC cells was abrogated by NF-jB inhibition. In com-
parison to sTWEAK, TNF causes a 6-fold induction for the
full-length and 3jB promoter and a 13-fold induction for the
98 base pair promoter, respectively. sTWEAK is thus a less
potent inducer of IL-8 promoter activity than TNF.
To investigate the possible involvement of GSK-3b in
sTWEAK-induced activation of NF-jB-dependent gene ex-
pression, the eﬀect of lithium chloride (a well-known GSK-3b
inhibitor) [29] was examined. As shown in Fig. 4C, lithium
chloride (40 mM) inhibited the eﬀect of sTWEAK on the full-
length (9%), 98 base pair (40%) and 3jB construct cells (53%).
Similar results were obtained using kenpaullone and GSK-3b
inhibitor I (both GSK-3b-speciﬁc inhibitors from Calbiochem)
(results not shown).4. Discussion
Members of the TNF family exist as transmembrane and
soluble forms that elicit distinct, and sometimes opposing, ef-
fects on inﬂammatory and apoptotic mechanisms [10].
TWEAK was predicted to be a type II membrane-boundprotein but it was suggested that it can also exert its apoptotic
activity in the soluble form [12,30]. We identiﬁed a shorter
form of TWEAK (shortTWEAK) to be an interaction partner
for GSK-3b through a Y2H screen using GSK-3b as bait. This
shortTWEAK protein consists of 40 AA more than sTWEAK.
The data presented above demonstrate that cells expressing
full-length TWEAK show morphological changes but sur-
vived, suggesting a diﬀerentiation type of event. This is ac-
cording to previous ﬁndings that TWEAK can induce
morphology changes or diﬀerentiation of cells, depending on
the cell type [10,17]. Transiently transfected shortTWEAK-E,
however, showed nuclear localization. This is the ﬁrst evidence
for TWEAK or shortTWEAK to be found in the nucleus and
this indicates that TWEAK and shortTWEAK may elicit
distinct eﬀects on signaling pathways.
The fact that GSK-3b and shortTWEAK colocalize in the
nucleus indicates that the Y2H results also have a physiological
64 A. De Ketelaere et al. / FEBS Letters 566 (2004) 60–64role in living cells. We did not succeed in conﬁrming the di-
rect interaction between TWEAK and GSK-3b through co-
immunoprecipitation but there might be a need for a third
interaction partner or a speciﬁc stimulus, necessary for inter-
action between both proteins.
GSK-3b localization was suggested to be regulated indirectly
through associations with binding proteins [9]. GSK-3b
phosphorylates and thereby regulates the nuclear export, DNA
binding and transcriptional activity of a large range of sub-
strates [31]. The ﬁnding that TWEAK can modulate the lo-
calization of GSK-3b thus raises the possibility that regulators
of TWEAK can indirectly aﬀect phosphorylation of various
other substrates by GSK-3b.
We propose that shortTWEAK and sTWEAK, having the
arginine-rich sequence in common, share the internalization
mechanism, as suggested for other arginine-rich membrane
permeable peptides [21]. This mechanism of internalization
oﬀers a new mode of action for TWEAK and an explanation
for previous results showing a TWEAK response in cells
without Fn14 expression (L929) [22]. We also observed a
TWEAK response in Jurkat cells (not expressing Fn14),
whereas others did not see any response [23].
The rapid degradation of IjBa and nuclear translocation of
p65, after addition of sTWEAK to the cells, suggested that
sTWEAK is a strong inducer of NF-jB activity. This is con-
sistent with previous results indicating that RAW cells (cells
without Fn14 expression) show rapid degradation of IjBa
after addition of TWEAK [17]. The hypothesis of TWEAK
internalization oﬀers an explanation to these ﬁndings, without
the involvement of a new TWEAK receptor.
Our results show that the translocation of sTWEAK, GSK-
3b and p65 to the nucleus in L929 and Jurkat cells is reﬂected
in at least one functional parameter, i.e., IL-8 promoter ac-
tivity. The fact that sTWEAK not only aﬀects the full length
IL-8 promoter the minimal NF-jB promoter (3jB) indicates
that the eﬀect is mainly caused by NF-jB activation. This is
also supported by Harada et al. [28] who suggested that the
TWEAK-induced secretion of IL-8 by HUVEC cells was
mediated by NF-jB activation.
An inhibitory eﬀect of LiCl on the IL-8 promoter activation
was observed during our experiments. We propose that the
eﬀect of GSK-3b on the NF-jB activation takes place at the
level of the p65 transactivation, as suggested by Hoeﬂich et al.
[1]. The diﬀerent levels of inhibition seem to be related to the
signiﬁcance of the NF-jB responsive element on the promoter
constructs: the larger the impact, the larger the inhibitory eﬀect
of LiCl.
Taken together, we have found that TWEAK has an eﬀect
on the NF-jB pathway and that GSK-3b participates in this
pathway. Speciﬁcally, (1) shortTWEAK bound to GSK-3b in
a Y2H assay, (2) shortTWEAK colocalized with GSK-3b in
the nucleus of living cells, (3) TWEAK is internalized into
living cells and translocates to the nucleus, (4) TWEAK
stimulation of cells causes the nuclear translocation of GSK-3b
and p65 and the degradation of IjBa and (5) the activation of
the IL-8 promoter by TWEAK can be inhibited by LiCl, a
commonly used GSK-3b inhibitor. This opens new perspec-
tives on the GSK-3b signal transduction pathways and the
modulation of inﬂammatory gene expression.References
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